Compare Bristol-Myers Squibb Co (BMY) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Centrus Energy Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while Centrus Energy Corp trades at $186.11 (market cap $3.77B). The key difference: Bristol-Myers Squibb Co is far larger — about 34.5× Centrus Energy Corp's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals.
| BMY | LEU | |
|---|---|---|
Market Cap | $129.94B | $3.77B |
Sector | Health | Energy |
52-Week High | $65.89 | $436.00 |
52-Week Low | $42.60 | $146.61 |
Enterprise Value | $163.92B | $3.08B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Centrus Energy (LEU) trades at $189.03, down 0.16% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 revenue of $176.1 million, beating expectations, but net income declined to $16.8 million from $28.9 million year-over-year due to higher costs. Recent developments include a $900 million DOE contract and a HALEU supply agreement with X-energy, positioning Centrus as a key player in the nuclear fuel supply chain with a $4.5 billion backlog.
The outlook for LEU is positive given its strategic role in nuclear energy expansion and strong institutional support, but risks include margin compression and execution challenges. Analysts maintain a buy consensus with a $228.50 price target, representing 21% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
